Antihypertensive drug treatment and fibrinolytic function

American Journal of Hypertension

Volumn 11, Issue 3 I, 1998, Pages 378-384

  Lottermoser, Katja ^a   Weisser, Burkhard ^a   Hertfelder, Hans Jörg ^a   Wöstmann, Bernd ^a   Vetter, Hans ^a   Düsing, Rainer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

receptor antagonists; blockers; Angiotensin converting enzyme inhibitors; Angiotensin II receptor antagonists; Calcium antagonists; Diuretics; Fibrinolytic system; Plasminogen activator inhibitor; Tissue type plasminogen activator

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ANTIHYPERTENSIVE ACTIVITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY THROMBOSIS; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOEMBOLISM;

ADRENERGIC ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIURETICS; FIBRINOLYSIS; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0031965541     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00496-2     Document Type: Review

References (54)

1. Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risk of stroke and coronary heart disease. Br Med Bull 1994;50:272-298.
2. McInnes GT: Hypertension and coronary artery disease: cause and effect. J Hypertens 1995;13(suppl. 2):S49-S56.
3. Mclnnes GT, Yeo WW, Ramsay LE, et al: Cardiotoxicity and diuretics: much speculation - little substance. J Hypertens 1992;10:317-335.
4. Chandler WL, Trimble SL, Loo SC, et al: Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990;76:930-937.
5. Prowse CV, Cash JD: Physiologic and pharmacologic enhancement of fibrinolysis. Semi Thromb Hemost 1984;10:51-60.
6. Marsh N, Gaffney P: Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980;238:9-11.
7. Cash JD: Control mechanisms of activator release, in Davidson JF, Rowan RM, Samama MM, Desnoyers PC (eds): Progress in Chemical Fibrinolysis and Thrombolysis. Raven Press, New York, 1978, pp 65-66.
8. Ferguson EW, Bernier LL, Banta GR, et al: Effects of exercise and conditioning on clotting and fibrinolytic activity in men. J Appl Phys 1987;62:1416-1419.
9. Wiman B, Mellbring G, Ranby M: Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127:279-283.
10. DeSouza CA, Dengel DR, Rogers MA, et al: The fibrinolytic system is not impaired in older men with hypertension. Hypertension 1996;27:1053-1058.
11. Kruithof EK, Gudinchet A, Bachmann F: Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988;59:7-9.
12. Colman RW, Hirsch J, Marder VJ: Thrombosis and Haemostasis, 3rd ed. JB Lippincott Company, Philadelphia, 1994, p 1604.
13. Astrup T, Mullertz S: The fibrin plate method for estimating fibrinolytic activity. Arch Biochem 1952;40:346-351.
14. Chohan IS: Piretanide: a new synthetic fibrinolytic and anti-platelet agent. Thromb Haemost 1986;56:360-363.
15. Chohan IS, Singh J, Vermylen J, Verstraete M: Effect of furosemide on plasma fibrinolytic activity and urokinase excretion. Exp Haemat 1977;5:153-157.
16. Pedersen OD, Gram J, Bagger H, et al: Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics. Coronary Artery Disease 1994; 5:617-623.
17. Winther K: The effect of β-blockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 1987; 10(suppl 2):S94-S98.
18. Winther K, Hedman C: Beta-adrenoceptor blockade, platelets, and rheologic factors. Cephalgia 1986;6(suppl 5):33-39.
19. Larsson PT, Wiman B, Olsson G, et al: Influence of metoprolol treatment on sympathoadrenal activation of fibrinolysis. Thromb Haemost 1990;63:482-487.
20. Teger-Nilsson A-C, Dahlöf C, Haglund E, et al: Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: a pilot study. J Clin Pharmacol 1990;30:S132-S137.
21. Jimenez AH, Tofler GH, Chen X, et al: Effects of nadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension. Am J Cardiol 1993;72:47-52.
22. Jansson J-H, Johansson B, Boman K, et al: Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 1991;40:321-326.
23. Gleerup G, Hedner T, Hjorting Hansen E, et al: Does antihypertensive therapy affect the natural protection against thrombosis? J Cardiovasc Pharmacol 1991; 18(suppl 3):S34-S36.
24. Wright RA, Perrie AN, Stenhouse F, et al: The long-term effect of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease. Eur J Clin Pharmacol 1994;46:279-282.
25. Gleerup G, Winther K: Decreased fibrinolytic activity and increased platelet function in hypertension. Am J Hypertens 1991;4:168S-171S.
26. Wright RA, Flapan AD, Alberti KG, et al: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
27. Jansson J-H, Boman K, Nilsson TK: Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993;44:485-488.
28. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
29. Vaughan DE, Rouleau J-L, Pfeffer MA: Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995; 16(supplement K):31-36.
30. Bridges AB, McLaren M, Belch JJ: A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients. Angiology 1995;46:811-817.
31. Soejima H, Ogawa H, Yasue H, et al: Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997;20:441-445.
32. Vaughan DE, Rouleau J-L, Ridker PM, et al, on behalf of the HEART Study Investigators: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-447.
33. Lottermoser K, Wöstmann B, Weisser B, et al: Effects of captopril on fibrinolytic function in healthy humans (abst). Am J Hypertens 1997;10:129A.
34. Brown NJ, Vaughan DE: ACE inhibition decreases PAI-1 in the setting of an activated RAS (abst). Hypertension 1997;30:514.
35. Seljeflot I, Moan A, Kjeldsen S, et al: Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996;27:1299-1304.
36. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 93-1099, 1993.
37. Kannel WB, Sorlie P: Hypertension in Framingham, in Paul O. (ed.): Epidemiology and Control of Hypertension. Stratton Int., New York, 1975, pp 553-592.
38. Freis ED: Race, sex and other indices of risk in hypertension. Am J Med 1973;55:275-280.
39. Rocha E, Paramo JA: The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis 1994;8:294-303.
40. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-278.
41. Jansson J-H, Johansson B, Boman K, et al: Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Int Med 1991;229:309-316.
42. Glueck CJ, Glueck HI, Hamer T, et al: β-Blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci 1994;307:317-324.
43. Potter van Loon BJ, Kluft C, Radder JK, et al: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993;42:945-949.
44. Juhan-Vague I, Alessi MC: Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70:138-143.
45. Ridker PM, Gaboury CL, Conlin PR, et al: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993;87:1969-1973.
46. Feener EP, Northrup JM, Aiello LP, et al: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-1362.
47. Vaughan DE, Lazos SA, Tong K: Angiotensin n regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995;95:995-1001.
48. Nishimura H, Tsuji H, Masuda H, et al: Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue-type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77:1189-1195.
49. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
50. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
51. Alderman MJ, Madhavan S, Ooi WL, et al: Renin-sodium profiling: a predictor of myocardial infarction among hypertensive patients. N Engl J Med 1991;324:1098-1104.
52. Alderman MJ, Ooi WL, Cohen H, et al: Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8.
53. Smith D, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985;66:835-839.
54. Hamdan AD, Quist WC, Gagne JB, et al: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996;93:1073-1078.